Latest studies
- RecruitingPHASE2
Pan Tumor Rollover Study
This study looks at the long-term safety of different cancer treatments, including nivolumab, alone or combined with other medicines. It's for people with various types of cancer who are already receiving treatment in a related study, aiming to see how these treatments work over time.
CancerSwitzerland - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)Switzerland - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseSwitzerland - Active not recruitingPHASE3
A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
This study is testing a new medicine called lutikizumab for people aged 12 and over with moderate to severe hidradenitis suppurativa (HS). It compares the new medicine to a dummy treatment (placebo) to see if it helps reduce HS symptoms and is safe.
Hidradenitis SuppurativaSwitzerland - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisSwitzerland - Active not recruitingNA
Multicenter Study to Evaluate the Clinical Outcome of the OmniTaper EV Implant in Single Tooth Restorations
This study tests a new titanium dental implant, the OmniTaper EV, for replacing single missing teeth. It aims to check its safety and effectiveness. The study involves regular dental visits over five and a half years at clinics in the UK and Europe.
Jaw, EdentulousSwitzerland - Active not recruitingPHASE2
A Phase 2 Study of Tarlatamab in Patients With Small Cell Lung Cancer (SCLC)
This study is testing a new medicine called tarlatamab for people with a type of lung cancer called Small Cell Lung Cancer (SCLC) that has come back or not responded to previous treatments. It aims to see how safe and effective the new medicine is.
Relapsed/Refractory Small Cell Lung CancerSwitzerland - Active not recruitingPHASE3
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
This study is looking at a new treatment called Tarlatamab for advanced small cell lung cancer that has come back after earlier treatment. We want to see if Tarlatamab helps people live longer compared to standard chemotherapy.
Small Cell Lung Cancer (SCLC)Switzerland - Active not recruitingPHASE3
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
This study is looking at a new medicine called romosozumab for children and teenagers aged 5-17 with Osteogenesis Imperfecta (brittle bone disease). It wants to see if romosozumab is better than existing bisphosphonate medicines at preventing broken bones and improving bone strength over 12 months.
Osteogenesis ImperfectaSwitzerland - RecruitingPHASE3
This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.
This study looks at a new combination treatment, Sigvotatug Vedotin plus pembrolizumab, for a type of lung cancer where a protein called PD-L1 is high. We want to see if this combination works better than pembrolizumab alone to help patients.
Non-Small Cell Lung CancerCarcinoma, Non-Small-Cell LungCarcinoma, Non-Small-Cell Lung (NSCLC)Switzerland - Active not recruitingPHASE3
An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care (SoC), Versus SoC Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
This study looks at a new treatment called 177Lu-PSMA-617 for men with advanced prostate cancer that has spread. It compares this new treatment alongside standard care to standard care alone, aiming to see if it helps patients live longer without their cancer getting worse.
Prostatic NeoplasmsSwitzerland - Active not recruitingPHASE3
A Study to Evaluate the Efficacy, Safety, and Tolerability of Using an Oral Once-daily 2 Drug Regimen Compared to an Oral Once-daily 3 Drug Regimen for the Treatment of Human Immunodeficiency Virus (HIV)-1 in Adults Who Have Not Previously Taken Antiretroviral Therapy
This study looks at two different daily pill combinations for adults newly diagnosed with HIV. It compares a two-drug treatment with a three-drug treatment to see which is safer and works better for controlling the virus.
HIVHIV InfectionsSwitzerland - Active not recruitingPHASE3
A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001)
This study looks at a new personalised treatment, Intismeran Autogene, combined with Pembrolizumab for high-risk melanoma. It aims to see if this combination can stop cancer from coming back better than Pembrolizumab alone after surgery, focusing on safety and effectiveness.
MelanomaSwitzerland - Active not recruiting
Micra Transcatheter Pacing System Post-Approval Registry
This study is looking at how a tiny pacemaker, the Micra Transcatheter Pacing System, works in everyday life after it's been approved. It's for people who need this type of pacemaker due to a slow heart rate (bradycardia) to check its safety and how well it works over time.
BradycardiaSwitzerland - RecruitingPHASE2, PHASE3
Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
This study keeps an eye on people who have had a special treatment called gene-modified T-cell therapy for cancer. It aims to check their health and how well the treatment worked over a long time, making sure it's safe and effective.
NeoplasmsSwitzerland - RecruitingPHASE3
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
This study is testing a new medicine, efruxifermin, for people with a serious liver condition called NASH/MASH cirrhosis. It's to see if the medicine helps improve liver health in those with scarring that hasn't yet caused severe problems.
NASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated SteatohepatitisSwitzerland - Active not recruitingPHASE3
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer
This study looks at a new drug, tucatinib, combined with T-DM1 to treat advanced HER2-positive breast cancer. It aims to see if this combination works better than T-DM1 alone for cancer that has spread or can't be removed by surgery.
HER2-positive Breast CancerSwitzerland - RecruitingPHASE3
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer
This study is testing if a new combination of medicines, including tucatinib, works better than current treatments for people with advanced HER2-positive bowel cancer. It also looks at side effects. Participants will be randomly assigned to receive either the new combination or standard care.
Colorectal NeoplasmsSwitzerland - RecruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
Carcinoma, Non-Small-Cell LungNeoplasm MetastasisSwitzerland - Recruiting
Product Surveillance Registry
This study keeps track of how well Medtronic medical devices, like those for heart problems or other conditions, work in real life. It aims to make sure these devices are safe and effective for patients.
Cardiac Rhythm DisordersUrological DisordersNeurological DisordersCardiovascular DisordersSwitzerland - Active not recruitingPHASE2
A Study of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Crohn's Disease
This study is looking at a new combination treatment, JNJ-78934804, for people aged 18-65 with Crohn's disease that is moderate to severe. It compares this new treatment to existing medicines, guselkumab and golimumab, to see how well it works over 48 weeks.
Crohn's DiseaseSwitzerland - RecruitingPHASE3
Randomised Clinical Trial to Investigate Efficacy and Safety of Benralizumab 30 mg SC as an add-on Therapy in Uncontrolled Eosinophilic Asthma Patients Treated With Medium-dose ICS-LABA Compared to Conventional Escalation to High-dose ICS-LABA Treatment
This study looks at a new treatment called benralizumab for people with severe asthma. It compares adding benralizumab to your usual asthma inhaler with just increasing the dose of your inhaler. We want to see if benralizumab helps control asthma better and is safe.
Eosinophilic AsthmaSwitzerland - Enrolling by invitation
European TIF2.0 Registry
This study looks at a keyhole procedure called TIF to treat reflux (heartburn and sickness). Doctors want to see how safe and effective it is for people experiencing symptoms like stomach acid coming up and a sore throat, sometimes combined with a small hernia repair.
Gastro -Oesophagal RefluxLaryngo-pharyngeal RefluxSwitzerland - Active not recruitingNA
Evaluation of TAVR Using the NAVITOR Valve in a Global Investigation
This study is looking at a new heart valve called NAVITOR. It's for people with severe aortic stenosis, a condition where one of your heart valves doesn't open properly. The study wants to see how safe and effective this new valve is at improving heart health.
Symptomatic Severe Aortic StenosisSwitzerland - Active not recruitingPHASE3
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
This study looks at new ways to treat children with a type of blood cancer called Acute Myeloid Leukaemia (AML). It compares different chemotherapy drugs, including a drug called gemtuzumab ozogamicin, and different types of stem cell transplants to find the most effective and safest treatments for young patients.
Acute Myeloid LeukaemiaSwitzerland - Active not recruitingPHASE3
Study of Vimseltinib for Tenosynovial Giant Cell Tumor
This study looks at a new drug, vimseltinib, for a condition called Tenosynovial Giant Cell Tumor (TGCT) when surgery isn't possible. It compares vimseltinib to a dummy drug for 24 weeks, then everyone gets the real drug. It aims to see how well it shrinks tumors.
Tenosynovial Giant Cell TumorPigmented Villonodular SynovitisGiant Cell Tumor of Tendon SheathTenosynovial Giant Cell Tumor, DiffuseSwitzerland - RecruitingPHASE3
Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
This study looks at a new drug, tebentafusp, for people with advanced melanoma that has already been treated. We want to see if tebentafusp, alone or with another drug called pembrolizumab, works better and is safer than standard treatments or best supportive care.
Advanced MelanomaSwitzerland - RecruitingPHASE3
The AIRTIVITY™ Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
This study is looking into a new medicine, BI 1291583, for people with bronchiectasis. It aims to see if this medicine can help reduce flare-ups, which are common with the condition. Participants will take a tablet daily and be monitored for up to 1 year and 8 months.
BronchiectasisSwitzerland - RecruitingNA
The Fourth Left Atrial Appendage Occlusion Study
This study looks at whether a 'WATCHMAN device' can prevent strokes in people with atrial fibrillation who are already taking blood thinners but still have a high stroke risk. It aims to see if blocking off a small part of the heart called the left atrial appendage helps.
Atrial FibrillationStroke, IschemicSystemic EmbolismSwitzerland - RecruitingNA
Endurant Stent Graft System vs Excluder Endoprothesis: ADVANCE Trial
This study compares two common medical devices, the Medtronic Endurant and Gore Excluder, used to treat a condition called Abdominal Aortic Aneurysm (AAA). It aims to see how well they shrink the aneurysm over time.
Abdominal Aortic AneurysmAbdominal Aortic Aneurysm >= 5.5 Centimeters in Male (Disorder)Abdominal Aortic Aneurysm >= 5.0 Centimeters in Female (Disorder)Switzerland - RecruitingPHASE3
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
This study looks at a new medicine, vicadrostat, for people with type 2 diabetes, high blood pressure, and heart disease. It aims to see if taking vicadrostat alongside empagliflozin can help reduce heart problems. Half the participants will get the study medicine, and half will get a dummy pill.
Diabetes Mellitus, Type 2HypertensionCardiovascular DiseasesSwitzerland - Active not recruitingPHASE2
Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer
This study is testing a new medicine called telisotuzumab vedotin for people with a specific type of advanced non-small cell lung cancer where a protein called c-Met is present. It aims to find out who benefits most and how well it works.
Non-small Cell Lung CancerSwitzerland - RecruitingPHASE1
A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors
This study is testing a new medicine, INCA33890, for people with advanced or spreading solid cancers. Doctors want to see how safe the medicine is, what side effects it causes, and find the best dose to give.
Solid TumorsAdvanced Solid TumorsMetastatic Solid TumorsSwitzerland - RecruitingPHASE3
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
This study is looking at a new medicine called nipocalimab for adults with moderate to severe lupus. It compares nipocalimab to a dummy treatment (placebo) to see if it can help reduce inflammation and improve lupus symptoms.
Lupus Erythematosus, SystemicSwitzerland - Active not recruitingPHASE3
A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer
This study looks at a new drug called tucatinib for HER2-positive breast cancer that has spread. We want to see if adding tucatinib to standard treatments (trastuzumab and pertuzumab) helps more than a dummy pill (placebo). It also checks for side effects.
HER2 Positive Breast CancerSwitzerland - Active not recruitingPHASE3
Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus
This study looks at a new tablet treatment, upadacitinib, for adults with moderate to severe lupus. It checks how safe and effective the medicine is and aims to reduce symptoms. Some people will get the active drug, others a dummy pill.
Systemic Lupus ErythematosusSwitzerland - Active not recruitingPHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
This study compares a new treatment called anitocabtagene autoleucel with standard care for people with multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new treatment works better.
Multiple MyelomaSwitzerland - Active not recruitingPHASE3
A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer
This study compares a new cancer drug called sigvotatug vedotin with a standard treatment, docetaxel, for advanced non-small cell lung cancer that has previously been treated. It aims to see if the new drug works better and what side effects it might cause.
Carcinoma, Non-Small-Cell LungSwitzerland - Recruiting
International Collaborative Gaucher Group (ICGG) Gaucher Disease Registry & Pregnancy Sub-registry
This study tracks the health of people with Gaucher disease over time, whether or not they are receiving treatment. There's also a sub-study for pregnant women with Gaucher disease to see how their pregnancies and babies' health progress. It helps doctors learn more about the condition.
Gaucher DiseaseCerebroside Lipidosis SyndromeGlucocerebrosidase Deficiency DiseaseGlucosylceramide Beta-Glucosidase Deficiency DiseaseSwitzerland - Recruiting
PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
This study looks at how blood thinners are used for pregnant people at risk of blood clots. It aims to understand the best ways to manage these medications during and after childbirth to keep mothers safe and healthy.
Pregnancy RelatedVenous ThromboembolismSwitzerland - Active not recruitingNA
10°C vs 4°C Lung Preservation RCT
This study is testing if keeping donor lungs at 10°C instead of the usual 4°C (on ice) before a lung transplant can reduce problems. The aim is to make lung transplants safer and more successful, allowing more flexibility for surgeons and patients.
Lung TransplantOrgan PreservationSwitzerland - RecruitingPHASE3
A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor.
This study looks at a special type of strong radiation, called SABR, for people with a few small cancer spots that have spread, along with a main tumor. It compares SABR plus usual care to just usual care to see if it helps.
Metastatic TumorSwitzerland - Active not recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Mitapivat in Pediatric Participants With Pyruvate Kinase Deficiency (PKD) Who Are Not Regularly Transfused, Followed by a 5-Year Extension Period
This study is for children aged 1 to 17 with a blood condition called Pyruvate Kinase Deficiency (PKD) who don't regularly need blood transfusions. It's testing a new medicine called mitapivat to see if it's safe and effective, compared to a dummy medicine.
Pediatric Pyruvate Kinase DeficiencyPediatric Hemolytic AnemiaSwitzerland - Active not recruiting
Validation and Standardization of Paramagnetic Rim Lesion (PRL) Identification in Multiple Sclerosis Across MAGNIMS Centers
This study looks at how consistently special brain scans (MRIs) are read across different hospitals for people with Multiple Sclerosis (MS). It aims to make sure everyone agrees on identifying specific 'rim lesions' in MS to help improve diagnosis and treatment plans for patients, using existing scan data only.
Multiple SclerosisSwitzerland - RecruitingNA
The DRAGON 2 Trial
The DRAGON 2 study looks at treating advanced bowel cancer that has spread to the liver. It compares a standard procedure called PVE with a newer one, PVE/HVE, to help the liver grow before surgery. This aims to make liver surgery safer for more people.
Colorectal Cancer Liver Metastases (CRLM)Small Future Liver Remnant (FLR)Switzerland - Available
Early Access Program With MaaT013 in Steroid-refractory Acute Gastrointestinal Graft Versus Host Disease
This early access program is for people with a serious gut condition called acute Graft-versus-Host Disease (aGvHD) that hasn’t responded to standard medicine (steroids). It's using an unapproved treatment called MaaT013 to see if it can help patients who have run out of other options.
Acute Graft Versus Host Disease in IntestineSteroid Refractory GVHDSwitzerland - Active not recruiting
STAR-LIFE: a Post-market Registry on MINIject
This study looks at a new tiny implant called MINIject for people with a common eye condition called open-angle glaucoma. It aims to see how well it works and if it's safe in real-life use over two years after surgery, gathering information from patients themselves.
Open Angle GlaucomaSwitzerland - Active not recruitingPHASE2
A Phase 2 Study of Anvumetostat in Participants With MTAP-deleted Advanced NSCLC (MTAPESTRY 201)
This study is looking into a new drug called anvumetostat for people with a specific type of advanced lung cancer (NSCLC) that's missing a gene called MTAP. We want to see how safe the drug is and if it helps by slowing down or shrinking the cancer.
MTAP-deleted NSCLCSwitzerland - Recruiting
Trifecta-Kidney cfDNA-MMDx Study
This study looks at new ways to check for rejection in kidney transplant patients. It compares a new blood test (DD-cfDNA) with a special biopsy test (MMDx) and traditional checks to see which is best at finding rejection accurately.
Kidney Transplant RejectionSwitzerland - Active not recruitingPHASE2
Radiochemotherapy +/- Durvalumab for Locally-advanced Anal Carcinoma. a Multicenter, Randomized, Phase II Trial of the German Anal Cancer Study Group
This study is testing if adding a drug called durvalumab to standard treatment (chemotherapy and radiation) works better for advanced anal cancer. Researchers want to see if this new combination improves how well people respond to treatment.
Anal CancerAnal CarcinomaAnal Cancer Stage IIIAnal Cancer Stage IISwitzerland